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Dementia is a syndrome of global and progressive impairment of cognitive abilities which is related to 
difficulties in performing normal daily activities. Brain-derived neurotrophic factor (BDNF) is a member of 
neurotrophin family which has been associated with dementia and cognitive decline. The aim of this study 
was to define the role of BDNF in the development of cognitive symptoms of dementia by analysing BDNF 
plasma concentration in patients with different types of dementia or diagnosed with mild cognitive 
impairment (MCI). 
The study included 207 patients with Alzheimer’s disease (AD), 59 patients with MCI and the total of 52 
patients with other non-AD types of dementia (dementia with Lewy bodies, frontotemporal and vascular 
dementia), diagnosed according to NINCDS-ADRDA and DSM-IV criteria. Cognitive impairment was 
evaluated using Mini-Mental Status Examination (MMSE) and Clock Drawing Test (CDT). Plasma BDNF 
levels were measured with enzyme-linked immunosorbent assay, according to the procedures supplied 
by the manufacturer (R&D Systems GmbH). The association of plasma BDNF levels with cognitive decline 
was evaluated using Kruskal–Wallis one-way analysis of variance and Spearman correlation coefficient. 
The results revealed increased BDNF concentration in plasma from patients with AD compared to subjects 
with MCI or other types of dementia (H=14.22; df=4; p=0.007). After dividing the patients with AD 
according to MMSE scores into patients with mild (mild AD), moderate (moderate AD), and severe 
cognitive impairment (severe AD), a significant (H=9.45; df=4; p=0.050) association between plasma BDNF 
levels and cognitive decline was detected, due to a significantly higher BDNF plasma levels in patients with 
moderate AD compared to patients with mild and severe AD, and compared to patients with MCI or non-
AD dementia. The study also points to the positive correlation between plasma BDNF concentration and 
the total CDT scores in a group of patients diagnosed with non-AD dementia (rs=0.34; p=0.028). 
This research further contributes to the current knowledge on the role of BDNF in the development of 
cognitive symptoms of dementia, with the purpose to offer new and easily accessible biochemical 
indicator of cognitive impairment and to provide new insights that will help us to better understand and 
treat these symptoms. 
